| Biotechnology Industry | Healthcare Sector | Mr. Louis James Panaccio BEC, C.A., M.A.I.C.D. CEO | CXA Exchange | - ISIN |
| Australia Country | - Employees | - Last Dividend | 4 Dec 2023 Last Split | - IPO Date |
Adherium Limited is a pioneer in the digital health technology sector, dedicated to addressing the challenges of sub-optimal medication usage in chronic diseases. With operations spanning New Zealand, Australia, Europe, and North America, the company has made significant strides since its inception in 2001. Based in Melbourne, Australia, Adherium is at the forefront of developing, manufacturing, and supplying innovative solutions aimed at enhancing patient adherence to medication regimens, particularly for chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Their commitment to healthcare innovation positions them as key players in improving patient outcomes and quality of life.
Adherium’s product lineup is centered around Hailie, a comprehensive asthma and COPD medication adherence tool, designed with the patient's needs in mind. Each offering is tailored to facilitate better management of chronic respiratory diseases through enhanced medication adherence and real-time patient feedback.